In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

R wave sensed from the left ventricle as mortality predictor in patients with cardiac resynchronization therapy for primary prevention

Session Poster Session 3

Speaker Belen Garcia Magallon

Congress : Heart Failure 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Poster Session
  • FP Number : P1532

Authors : N G Uribe Heredia (Guadalajara,ES), R Peinado Peinado (Madrid,ES), JL Balaguer Recena (Guadalajara,ES), LG Piccone Saponara (Ciudad Real,ES), S Moreno Reviriego (Guadalajara,ES), C Solorzano Guillen (Guadalajara,ES), JL Peyrat Benitez (Guadalajara,ES), R Arroyo Espliguero (Guadalajara,ES), ME Jimenez Martinez (Guadalajara,ES), C Toran Martinez (Guadalajara,ES), A Castillo Sandoval (Guadalajara,ES), JL Garcia Gonzalez (Guadalajara,ES), E Novo Garcia (Guadalajara,ES), B Garcia Magallon (Guadalajara,ES), ME Viana Llamas (Guadalajara,ES)

N G Uribe Heredia1 , R Peinado Peinado2 , JL Balaguer Recena1 , LG Piccone Saponara3 , S Moreno Reviriego1 , C Solorzano Guillen1 , JL Peyrat Benitez1 , R Arroyo Espliguero1 , ME Jimenez Martinez1 , C Toran Martinez1 , A Castillo Sandoval1 , JL Garcia Gonzalez1 , E Novo Garcia1 , B Garcia Magallon1 , ME Viana Llamas1 , 1University Hospital of Guadalajara - Guadalajara - Spain , 2University Hospital La Paz, Arrhythmia Unit - Madrid - Spain , 3Hospital General de Ciudad Real, Nefrology - Ciudad Real - Spain ,


BACKGROUND: A lower left ventricular R wave (LVRW)  and a higher left ventricular threshold (LVT) could be related to a greater extent of myocardial scarring and lower myocardial vitality.

PURPOSE: The purpose of this study was to analyze the value of left ventricular (LV) electrode measurements during the implant as predictors of mortality in patients with implantable cardioverter-defibrillator (ICD) with cardiac resynchronization therapy (CRT) in primary prevention.

METHODS: We retrospectively analyzed data of patients with implanted biventricular defibrillator between January 2010 and December 2013. CRT was indicated according to the guidelines of the ESC. During the implant, left ventricular sensing, impedance and threshold were measured. Clinical characteristics, left ventricular lead position and measurements, electrocardiography and echocardiography were evaluated before and after CRT. Statistical analysis SPSS 20. The variables were compared bye T-Student and Chi2. Multivariate analysis logistic regression. Statistical significance for p <0.05.

RESULTS: 43 patients were enrolled. Mean age was 72 y and 90% were men.  Ischemic cardiomyopathy 49%. NYHA functional class III-IV 63%. LBBB was identified in 46,5% and permanent atrial fibrillation (AF) 35%.  After the implant mean biventricular paced QRSd was 128±21ms. The mean duration of follow-up was 33.3±7.8 months. The mortality rate was 19% (N=8). The univariate analysis is detailed in table 1. With multivariate analysis, only a lower LVRW during the implant (6.1±3.1V vs 14.8±7.6V, OR 1.3, 95% CI 1.03-1.7, p=0.03) and a very low LVEF after the implant (32.5±10.9 Vs 45.9±10.6, OR 1.14, 95% CI 1.03-1.3, p=0,03) remained as independent predictors factors of mortality.

CONCLUSIONS: In our study, a lower left ventricular detection and a very low LVEF were independent predictors of mortality. However, a higher left ventricular threshold did not reach statistical significance. These variables could identify a subgroup of patients who would benefit from a closer follow-up.






Paced QRSd (ms)







< 0,001

LVT (V x 0,5ms)




LVEF postCRT%)




Absence of reverse remodelling (%)







< 0,001

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are